Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

Table 4 Adverse events, compliance and relief of symptoms in the 14d-EA group and the 14d-B-quadruple group, n (%)

Adverse events, compliance and relief of symptoms	Total (n = 439)	14d-EA group (n = 221)	14d-B-quadruple group (n = 218)	P value
Patients with adverse events (yes/no)	30/409 (6.83)	11/210 (4.98)	19/199 (8.72)	0.121
Variety of adverse events
Changes in bowel habits (yes/no)	7/432 (1.59)	2/219 (0.90)	5/213 (2.29)	0.435
Skin rash (yes/no)	5/434 (1.14)	3/218 (1.36)	2/216 (0.92)	1.000
Bitter taste in mouth (yes/no)	5/434 (1.14)	0/221 (0.00)	5/213 (2.29)	0.070
Abdominal discomfort (yes/no)	5/434 (1.14)	2/219 (0.90)	3/215 (1.38)	0.988
Nausea (yes/no)	3/436 (0.68)	0/221 (0.00)	3/215 (1.38)	0.242
Poor appetite (yes/no)	3/436 (0.68)	2/219 (0.90)	1/217 (0.46)	1.000
Dizziness (yes/no)	2/437 (0.46)	2/219 (0.90)	0/218 (0.00)	0.499
Others (yes/no)	5/434 (1.14)	1/220 (0.45)	4/214 (1.83)	0.360
Discontinued drugs because of adverse events (yes/no)	4/435 (0.91)	1/220 (0.45)	3/215 (1.38)	0.606
Good compliance (yes/no)	432/7 (98.41)	217/4 (98.19)	215/3 (98.62)	1.000
Relief of symptoms (yes/no)	322/15 (n = 337) (95.55)	156/9 (n = 165) (94.55)	166/6 (n = 172) (96.51)	0.382

P values were obtained from two-sided comparisons of difference between the 14d-EA group and the 14d-B-quadruple group. EA: Esomeprazole-amoxicillin; B-quadruple: Esomeprazole-amoxicillin-clarithromycin-bismuth.